Richard Pellegrino Is Appointed New Chief Research and Development Officer of Grenova

Grenova, Inc., a Virginia-based designer, manufacturer, and distributor of instruments and associated consumables for the life sciences industry, today announced the appointment of Richard Pellegrino as Chief Research and Development Officer.

Richard Pellegrino joins Grenova during a period of rapid growth as the company expands its award-winning team designed to make the life sciences industry environmentally friendly, cost-effective, and efficient.

“From the bench to the board room, Richard has an unmatched reputation for leading high-performing research and development teams throughout his impressive career,” said Lane Major, President and Chief Executive Officer of Grenova. “Richard will make an immediate impact as Grenova continues to grow its team of industry leaders committed to proprietary technology that is providing a unique economic, environmental, and supply chain value proposition to our customers around the world.”

Pellegrino brings decades of experience in research and development, as well as a steadfast commitment to innovation, to Grenova having served as a key member of executive teams and an R&D subject matter expert for startup, mid-sized, and Fortune 500 businesses. He has shepherded organizations through all stages of growth — from raising $9M in venture capital to found Relievant Medsystems, to leading an R&D team through an IPO and integrating them into the fabric of Stryker’s Spine Division following the $1.4B acquisition of K2M, Inc. Pellegrino also serves as an Entrepreneur in Residence (EIR) for the VCU tech transfer group and is a named inventor on more than 60 issued patents.

“I was inspired to join Grenova because it’s a first-to-market innovator that has created technology capable of transforming the entire life sciences industry and beyond,” said Pellegrino. “Driven by radical innovation and a constant pursuit of new ideas, Grenova’s products are creating a more sustainable future while lowering costs in the laboratory industry and increasing efficiencies as its impact is felt across the globe.”

SourceGrenova

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”